A TRP family based signature for prognosis prediction in head and neck squamous cell carcinoma
Journal of Oncology Feb 02, 2022
A robust risk signature based on transient receptor potential family genes (TFGs) for prognosis evaluation in head and neck squamous cell carcinoma (HNSCC) was developed, and the TFGs-based signature (TFBS) proposed herein could be a favorable indicator to predict the survival outcome in HNSCC and provides prominent treatment guidance.
Using HNSCC sample data from the TCGA website, experts integrated expression profiles of TFGs for 490 HNSCC cases.
Screening of 6 TFGs (TRPC1, TRPC3, TRPC6, TRPV2, TRPV4, and TRPM8) closely linked with prognosis of HNSCC cases was conducted to construct TFBS.
A dismal patient outcome in the TFBS-high group was predicted by TFBS.
On Cox regression, favorable independent value of TFBS was evident.
In receiver operating characteristic analysis, TFBS demonstrated robust power for predicting prognosis.
In gene set enrichment analysis, various important pathways associated with HNSCC were unveiled, including the p53 pathway, TNF-alpha signaling via NFKB, and hypoxia.
Patients in the TFBS-high group were more likely in immunosuppressive status.
Exclusive Write-ups & Webinars by KOLs
Daily Quiz by specialty
Paid Market Research Surveys
Case discussions, News & Journals' summaries